Telescope Innovations Corp · CSE:TELI
Telescope Innovations — Investor Presentation (March 2024)
17 slides from Telescope Innovations's investor presentation, March 2024
Slide 1: Fewer Experiments. More Insight.
FEWER EXPERIMENTS. MORE INSIGHT.
Slide 2: Disclaimer and forward-looking information
TELI (CSE) The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, acc
Slide 3: Our Company
TELI (CSE) OUR COMPANY TELIF (OTCQB) We build intelligent automation platforms that accelerate chemical process development, increase data quality, and reduce development costs. AUTOMATION & ADVANCED ARTIFICIAL PROCESS ROBOTICS ANALYTICAL TECHNOLOGY INTELLIGENCE DEVELOPMENT TELI (CSE) TELIF (OTCQB)
Slide 4: Who We Are
TELI (CSE) WHO WE ARE Our award-winning scientific leadership includes a 2-time Nobel Prize Winner in Chemistry. TELIF (OTCQB) We have collectively authored over 450 academic publications and 34 patents. PROF. JASON HEIN DR. BARRY SHARPLESS HENRY DUBINA DR. JEFF SHERMAN JOHN KIRINCIC CTO AND DIRECTOR
Slide 5: Our Board of Directors
TELI (CSE) OUR BOARD OF DIRECTORS Our directors bring over 80 years combined experience in building technology companies and TELIF (OTCQB) successfully managing companies in the capital markets. DR. ANDY ROBINSON ROBERT MINTAK ALI PEJMAN PROF. JASON HEIN HENRY DUBINA An experienced scientist with a
Slide 6: Our Vision
OUR VISION 1 2 3 International leadership in online Provider-of-choice for Global deployment in chemical and chemistry sampling and analysis products Self-Driving Laboratories pharmaceutical process development telescopeinnovations.com 6
Slide 7: Our Business Model: Technology Development
TELI (CSE) OUR BUSINESS MODEL: TECHNOLOGY DEVELOPMENT TELIF (OTCQB) WORLD-CLASS SCIENTISTS We’ve collectively authored over 450 academic publications and 34 patents. New IP enriches our team and partnerships. R&D WITH NEW MARKET-DRIVEN IP PRODUCT STRATEGIC & KNOW-HOW DEVELOPMENT INDUSTRIAL CLIENTS A
Slide 8: Our Business Model: Revenue Generation
TELI (CSE) OUR BUSINESS MODEL: REVENUE GENERATION TELIF (OTCQB) Workflow automation, process chemistry R&D SERVICES REVENUES WORLD-CLASS SCIENTISTS Global distribution partnerships PRODUCT SALES R&D WITH STRATEGIC NEW MARKET-DRIVEN IP PRODUCT INDUSTRIAL & KNOW-HOW DEVELOPMENT CLIENTS IP Monetizing ou
Slide 9: Flagship Product: DirectInject-LC
TELI (CSE) FLAGSHIP PRODUCT A process analytical technology for automated TELIF (OTCQB) analysis of chemical reactions DIRECTINJECT - LC™ In first year of launch, units are deployed at 13 of the top 20 pharma companies in the “...automation, lab digitization, world and data-rich experimentation aren’
Slide 10: Global Process Analytical Technology (PAT) Market
TELI (CSE) GLOBAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET* KEY TELIF (OTCQB) ● Massive, increasing R&D spending in pharma and biotech DRIVERS ● Need for automation and quality control in pharmaceutical manufacturing GLOBAL MARKET SIZE 2021 BREAKDOWN BY TECHNIQUE $4.3 B DirectInject-LC 4 addresses
Slide 11: Strong Investments in Self-Driving Laboratories (SDLs)
STRONG INVESTMENTS IN SELF-DRIVING LABORATORIES (SDLs) $CAD$CAD 500 M500 | 2023 M £ 81 M | 2018 Acceleration Consortium $200 M from government (CFREF) $200 M: Largest Canadian federal research grant (CFREF) Materials Innovation Factory + $300 M: Matching by industry & academic partners $300 M in mat
Slide 12: Strategic Partners and Clients
TELI (CSE) STRATEGIC PARTNERS AND CLIENTS TELIF (OTCQB) INSTRUMENTATION & PHARMACEUTICAL ENGINEERING & MINING GOVERNMENT TECHNOLOGY COMPANIES COMPANIES AND ACADEMIA PARTNERS telescopeinnovations.com 12 CONFIDENTIAL DRAFT
Slide 13: Building a Successful Track Record
TELI (CSE) BUILDING A SUCCESSFUL TRACK RECORD Repeat clients for TELIF (OTCQB) Self-Driving Labs in chemical and DIRECTINJECT - LC™ Second profitable pharmaceutical quarter closed deployed by 13 of top 20 pharma Global distribution manufacturing (Q3, FY2023) companies in the world partnership for DIR
Slide 14: Key Business Plan Elements for 2024 and 2025
TELI (CSE) KEY BUSINESS PLAN ELEMENTS FOR 2024 AND 2025 SAMPLING / ANALYSIS SELF-DRIVING CHEMICAL / PHARMA TELIF (OTCQB) PRODUCTS LABORATORIES PROCESS DEVELOPMENT Global distribution of Formalize consortium of key Maintain and expand process DIRECTINJECT - LC via market- pharma companies to fund res
Slide 15: Strong Growth in First Years
TELI (CSE) STRONG GROWTH IN FIRST 2 YEARS TELIF (OTCQB) ● Revenue-positive in first full fiscal year (FY 2022) ● 375% increase in revenue from FY 2022 to FY 2023 ● Major development in FY 2024: Global Distribution Agreement signed with Market-leading vendor (Mettler Toledo AutoChem) for DirectInject-L
Slide 16: Capitalization
TELI (CSE) CAPITALIZATION STOCK TICKER SYMBOLS TELIF (OTCQB) TELI (CSE), TELIF(OTCQB) CAPITAL STRUCTURE PRICE NUMBER December 2023 Average Shares issued 53,665,569 Stock options $ 0.54 4,283,050 Warrants $ 0.75 2,439, 749 Fully Diluted Share Position 60,388,749 Shares held by Directors / Officers - 1
Slide 17: Thank You
THANK YOU Contact: investors@telescopeinn.com
Telescope Innovations — Investor Presentation (March 2024) on 6ix